Bone Tumors in Adolescents and Young Adults

  • Stefan S. Bielack
  • Dorothe Carrle
  • Jendrik Hardes
  • Andreas Schuck
  • Michael Paulussen
Pediatric Malignancies

Opinion statement

Bone tumors, particularly osteosarcomas and members of the Ewing Sarcoma Family of Tumors (ESFT), are typical malignancies of adolescents and young adults. Current diagnostic and therapeutic guidelines for patients of all ages were developed in this specific age group. The aim of bone sarcoma therapy should be to cure the patient from both the primary tumor and all (micro-)metastatic deposits while maintaining as much (extremity) function and causing as few treatment-specific late effects as possible. Bone sarcoma therapy requires close multidisciplinary cooperation. Usually, it consists of induction chemotherapy, followed by local therapy of the primary tumor (and, if present, primary metastases) and further, adjuvant chemotherapy. Local treatment for osteosarcoma should be surgery whenever feasible. Surgery is also gaining importance in ESFT, which was long considered a domain of radiotherapy. Modern reconstructive techniques continue to expand the indications for limb salvage, particularly for patients who have not yet reached skeletal maturity. Treatment within the framework of prospective, multi-institutional trials should be considered standard of care not only for children, but also for affected adolescents and (young) adults. Such trials are essential in guaranteeing that all patients have access to appropriate care and that progress from biological studies can be translated into prognostic improvements without undue delay. The rarity of bone sarcomas increasingly requires trials to be multinational.

References and Recommended Reading

Papers of particular interest, published recently, has been highlighted as: •Of importance ••Of major importance

  1. 1.
    Gloeckler Ries LA, Reichman ME, Riedel Lewis D, Hankey BF, Edwards BK: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541–552PubMedCrossRefGoogle Scholar
  2. 2.
    Bleyer A, Viny A, Barr R: Cancer in 15- to 29-year-olds by primary site. Oncologist 2006, 11:590–601PubMedCrossRefGoogle Scholar
  3. 3.
    Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 225–419Google Scholar
  4. 4.
    Chow WA: Update on chondrosarcomas. Curr Opin Oncol 2007, 19:371–376PubMedCrossRefGoogle Scholar
  5. 5.•
    Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E: Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2124–2135PubMedCrossRefGoogle Scholar

This combined analysis of data from 59 European cancer registries shows that survival rates for children and adolescents with bone tumors have not improved since the mid-1980s.

  1. 6.••
    Bleyer A, Montello M, Budd T, Saxman S: National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer 2005, 103:1891–1897PubMedCrossRefGoogle Scholar

Adolescents and young adults with sarcoma had lower rates of trial participation and smaller increases of survival expectancies over time than those of other age groups in this North American analysis.

  1. 7.•
    Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002, 20:776–790PubMedCrossRefGoogle Scholar

Clinical prognostic factors for osteosarcoma were evaluated in this large series of 1.702 unselected osteosarcoma patients from the COSS group.

  1. 8.
    Bielack SS, Machatschek JN, Flege S, Jürgens H: Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004, 5:1243–1256PubMedCrossRefGoogle Scholar
  2. 9.•
    Kager L, Zoubek A, Pötschger U, et al.: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21:2011–2018PubMedCrossRefGoogle Scholar

This is the largest series of patients with primary metastatic osteosarcoma.

  1. 10.•
    Kager L, Zoubek A, Kastner U, et al.: Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006, 24:1535–1541PubMedCrossRefGoogle Scholar

Other than commonly assumed, patients with skip-metastases were found to have relatively good outcomes if treated with multidrug chemotherapy and surgery of all affected sites.

  1. 11.
    Goorin AM, Schwartzentruber DJ, Devidas M, et al.: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003, 21:1574–1580PubMedCrossRefGoogle Scholar
  2. 12.
    Fuchs N, Bielack SS, Epler D, et al.: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998 9:893–899PubMedCrossRefGoogle Scholar
  3. 13.
    Bacci G, Briccoli A, Ferrari S, et al.: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 2001, 37:2030–2039PubMedCrossRefGoogle Scholar
  4. 14.
    Smeland S, Muller C, Alvegard TA, et al.: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003, 39:488–494PubMedCrossRefGoogle Scholar
  5. 15.
    Ferrari S, Smeland S, Mercuri M, et al.: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005, 23:8845–8852PubMedCrossRefGoogle Scholar
  6. 16.
    Petrilli AS, de Camargo B, Filho VO, et al.: Results of the Brazilian Osteosarcoma Treatment Group studies III and IV: Prognostic factors and impact on survival. J Clin Oncol 2006, 24:1161–1168PubMedCrossRefGoogle Scholar
  7. 17.
    Le Deley MC, Guinebretière JM, Gentet JC, et al.: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007, 43:752–761PubMedCrossRefGoogle Scholar
  8. 18.•
    Lewis IJ, Nooij MA, Whelan J, et al.: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112–128PubMedCrossRefGoogle Scholar

Increasing chemotherapy dose intensity by adding G-CSF did not lead to higher cure rates in this randomized trial.

  1. 19.
    Meyers PA, Schwartz CL, Krailo M, et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23:2004–2011PubMedCrossRefGoogle Scholar
  2. 20.•
    Meyers PA, Schwartz C, Krailo M, et al.: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children’s Oncology Group. J Clin Oncol 2008, 26:633–638PubMedCrossRefGoogle Scholar

Adding ifosfamide did not improve EFS or overall survival, while the immune modulator MTP was associated with significantly improved survival in this largest published randomized osteosarcoma trial.

  1. 21.
    Longhi A, Ferrari S, Bacci G, Specchia S: Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drug 2007, 18:737–744CrossRefGoogle Scholar
  2. 22.
    Aquerreta I, Aldaz A, Giráldez J, Sierrasesúmaga L: Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer 2004, 42:52–58PubMedCrossRefGoogle Scholar
  3. 23.
    Crews KR, Liu T, Rodriguez-Galindo C, et al.: High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004, 100:1724–1733PubMedCrossRefGoogle Scholar
  4. 24.
    Zelcer S, Kellick M, Wexler LH, et al.: Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005, 44:638–642PubMedCrossRefGoogle Scholar
  5. 25.
    Tunn PU, Reichardt P: Chemotherapy for osteosarcoma without high-dose methotrexate: a 12-year follow-up on 53 patients. Onkologie 2007, 30:228–232PubMedCrossRefGoogle Scholar
  6. 26.•
    Widemann BC, Balis FM, Kempf-Bielack B, et al.: High-dose methotrexate-induced nephrotoxicity: incidence in osteosarcoma. Patients, treatment and outcome. Cancer 2004, 100:2222–2232PubMedCrossRefGoogle Scholar

This large intergroup effort defines the incidence of HD-MTX related nephrotoxicity and describes outcomes.

  1. 27.
    Flombaum CD, Meyers PA: High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999, 17:1589–1594PubMedGoogle Scholar
  2. 28.
    Lewis IJ, Weeden S, Machin D, et al.: Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol 2000, 18:4028–4037PubMedGoogle Scholar
  3. 29.
    Eselgrim M, Grunert H, Kühne T, et al.: Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 2006, 47:42–50PubMedCrossRefGoogle Scholar
  4. 30.
    Sauerbrey A, Bielack S, Kempf-Bielack B, et al.: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001, 27:933–937PubMedCrossRefGoogle Scholar
  5. 31.
    Fagioli F, Aglietta M, Tienghi A, et al.: High-dose chemotherapy in the treatment of relapsed osteosarcoma: An italian sarcoma group study. J Clin Oncol 2002, 20:2150–2156PubMedCrossRefGoogle Scholar
  6. 32.
    Carrle D, Dantonello T, Bielack SS: Meeting report: Pan-European Sarcoma Trials: moving forward in a climate of increasing economic and regulatory pressure. Sarcoma 2007, Article ID 76405, 7 pages, doi:10.1155/2007/76405
  7. 33.
    Goorin AM, Harris MB, Bernstein M, et al.: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. J Clin Oncol 2002, 20:426–433PubMedCrossRefGoogle Scholar
  8. 34.
    Müller CR, Smeland S, Bauer HC, Saeter G, Strander H: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005, 44:475–480PubMedCrossRefGoogle Scholar
  9. 35.
    Craft A, Cotterill S, Malcolm A, et al.: Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998, 16:3628–3633PubMedGoogle Scholar
  10. 36.
    Oberlin O, Deley MC, Bui BN, et al.: Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001, 85:1646–1654PubMedCrossRefGoogle Scholar
  11. 37.
    Paulussen M, Ahrens S, Dunst J, et al.: Localized Ewing tumor of bone: Final results of the cooperative Ewing’s sarcoma study CESS 86. J Clin Oncol 2001, 19:1818–1829PubMedGoogle Scholar
  12. 38.•
    Grier HE, Krailo MD, Tarbell NJ, et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694–701PubMedCrossRefGoogle Scholar

This is the key reference supplying randomized evidence from a large trial that adding ifosfamide plus etoposide to the former standard of vincristine, doxorubicin, and cyclophosphamide improves outcome in ESFT.

  1. 39.
    Euro-E.W.I.N.G.Study Committee: EURO-E.W.I.N.G. 99 Study Manual—EUROpean Ewing Tumour Initiative of National Groups Ewing Tumour Studies 1999. http://euro-ewing.uni-muenster.de/, 2007
  2. 40.
    Cangir A, Vietti TJ, Gehan EA, et al.: Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer 1990, 66:887–893PubMedCrossRefGoogle Scholar
  3. 41.
    Paulussen M, Ahrens S, Burdach S, et al.: Primary metastatic (stage IV) Ewing tumor. Survival analysis of 171 patients from the EICESS studies. Ann Oncol 1998, 9:275–281PubMedCrossRefGoogle Scholar
  4. 42.
    Meyers PA: High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004, 16:120–125PubMedCrossRefGoogle Scholar
  5. 43.
    Jürgens C, Weston C, Lewins I, et al.: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006, 47:22–29CrossRefGoogle Scholar
  6. 44.
    Manfrini M: The role of vascularized fibula in skeletal reconstruction. Chir Organi Mov 2003, 88:137–142PubMedGoogle Scholar
  7. 45.
    Hardes J, Gebert C, Hillmann A, et al.: Die Möglichkeiten und Grenzen der Umkehrplastik im operativen Behandlungsplan der primär malignen Knochentumoren. Orthopäde 2003, 32:965–970PubMedCrossRefGoogle Scholar
  8. 46.••
    Baumgart R, Hinterwimmer S, Krammer M, et al.: The bioexpandable prosthesis: a new perspective after resection of malignant bone tumors in children. J Pediatr Hematol Oncol 2005, 27:452–455PubMedCrossRefGoogle Scholar

In this publication a new (biological) growing prosthesis was introduced, which did not lengthen the prosthesis but the adjacent bone.

  1. 47.
    Krepler P, Dominkus M, Toma CD, et al.: Endoprosthesis management of the extremities of children after resection of primary malignant bone tumors. Orthopäde 2003, 32:1013–1019PubMedCrossRefGoogle Scholar
  2. 48.
    Abudu A, Grimer RJ, Tillman R, et al.: The use of prostheses in skeletally immature patients. Orthop Clin North Am 2006, 37:75–84PubMedCrossRefGoogle Scholar
  3. 49.
    De Wilde L, Sys G, Julien Y, et al.: The reversed Delta shoulder prosthesis in reconstruction of the proximal humerus after tumour resection. Acta Orthop Belg 2003, 69:495–500PubMedGoogle Scholar
  4. 50.•
    Gosheger G, Hardes J, Ahrens H, et al.: Silver-coated megaendoprostheses in a rabbit model—an analysis of the infection rate and toxicological side-effects. Biomaterials 2004, 25:5547–5556PubMedCrossRefGoogle Scholar

In this publication, better antimicrobial activity of silver compared to titanium against staphylococcus aureus was shown.

  1. 51.
    Bacci F, Ferrari S, Longhi A, et al.: Role of surgery in local treatment of Ewing’s sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 2004, 11:111–120PubMedGoogle Scholar
  2. 52.
    Schuck A, Hofmann J, Rube C, et al.: Radiotherapy in Ewing’s sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys 1998, 42:1001–1006PubMedGoogle Scholar
  3. 53.•
    Schuck A, Ahrens S, Paulussen M, et al.: Local therapy in localized Ewing tumors: Results of 1.058 patients treated in the CESS 81, CESS 86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003, 55:168–177PubMedCrossRefGoogle Scholar

This and reference [54] are the largest analyses concerning the merits of different local therapy approaches in ESFT.

  1. 54.•
    Bacci G, Longhi A, Briccoli A, et al.: The role of surgical margins in treatment of Ewing’s sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Incol Biol Phys 2006, 65:766–772CrossRefGoogle Scholar

This and reference [53] are the largest analyses concerning the merits of different local therapy approaches in ESFT.

  1. 55.
    Krasin M, Rodriguez-Galindo C, Billups C, et al.: Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: Outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2004, 60:830–838PubMedCrossRefGoogle Scholar
  2. 56.
    Paulino A, Nguyen T, Mai W, The B, Wen B. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 2007, 49:145–148PubMedCrossRefGoogle Scholar
  3. 57.•
    Machak GN, Tkachev SI, Solovyev YN, et al.: Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clin Proc 2003, 78:147–155PubMedCrossRefGoogle Scholar

In this publication, a detailed analysis of the outcome of radiotherapy in patients with osteosarcoma and no or insufficient resections is given.

  1. 58.
    DeLaney TF, Park L, Goldberg SI, et al.: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005, 61:492–498PubMedGoogle Scholar
  2. 59.•
    Kempf-Bielack B, Bielack SS, Jürgens H, et al.: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005, 20(23):559–568Google Scholar

Number of lesions and recurrence free-interval correlated with postrecurrence outcomes in this large series of 576 patients. Complete surgery was a prerequisite for cure, and second-line chemotherapy seemed to improve outcomes.

  1. 60.
    Ferrari S, Briccoli A, Mercuri M, et al.: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003, 21:710–715PubMedCrossRefGoogle Scholar
  2. 61.
    Meyer WH, Pratt CB, Poquette CA, et al.: Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children’s Research Hospital OS-91 trial. J Clin Oncol 2001, 19:171–182PubMedGoogle Scholar
  3. 62.
    Saylors RL III, Stine KC, Sullivan J, et al.: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001, 19:3463–3469PubMedGoogle Scholar
  4. 63.
    Anderson P, Nuñez R: Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007, 7:1517–1527PubMedCrossRefGoogle Scholar
  5. 64.
    Whelan JS, McTiernan A, Kakouri E, et al.: Carboplatin-based chemotherapy for refractory and recurrent Ewing’s tumours. Pediatr Blood Cancer 2004, 43:237–242PubMedCrossRefGoogle Scholar
  6. 65.
    Wagner LM, McAllister N, Goldsby RE, et al.: Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007, 48:132–139PubMedCrossRefGoogle Scholar
  7. 66.•
    Maksimenko A, Malvy C: Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets 2005, 9:825–830PubMedCrossRefGoogle Scholar

This report proves that the molecular rearrangement in ESFT is the ultimate cause for the manifestation of the malignant phenotype, and that it can be reversed in principal.

  1. 67.
    Martins AS, Mackintosh C, Martin DH, et al.: Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532–3540PubMedCrossRefGoogle Scholar
  2. 68.
    Lissat A, Vraetz T, Tsokos M, et al.: Interferon-gamma sensitizes resistant Ewing’s sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007;170:1917–1930PubMedCrossRefGoogle Scholar
  3. 69.
    Myatt SS, Burchill SA: The sensitivity of the Ewing’s sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity. Oncogene 2007, 7:985–996Google Scholar
  4. 70.
    Völker T, Denecke T, Steffen I, et al.: Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007, 25:5435–5441PubMedCrossRefGoogle Scholar
  5. 71.
    Schuetze MS: Utility of PET in sarcomas. Current Opin Oncol 2006, 18:369–373CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Stefan S. Bielack
    • 1
    • 2
  • Dorothe Carrle
    • 1
  • Jendrik Hardes
    • 3
  • Andreas Schuck
    • 4
  • Michael Paulussen
    • 5
  1. 1.Klinik für Kinder- und Jugendmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie)Klinikum Stuttgart, OlgahospitalStuttgartGermany
  2. 2.Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und OnkologieUniversitätsklinikum MünsterMunsterGermany
  3. 3.Klinik und Poliklinik für Allgemeine OrthopädieUniversitätsklinikum MünsterMunsterGermany
  4. 4.Department of RadiotherapyUniversity Hospital MuensterMunsterGermany
  5. 5.Universitäts-Kinderspital beider Basel (UKBB)BaselSwitzerland

Personalised recommendations